BioBalance Announces the Resignation of Its CEO and the Assumption of Additional Duties By Richard Serbin (RedNova)
BioBalance Corp. (BioBalance), a wholly owned subsidiary of New York Health Care, Inc. (OTCBB: BBAL), filed a Form 8-K on September 12, 2006, to announce the resignation of its CEO, Dennis O'Donnell, on September 6, 2006. The Company is now actively searching for a new CEO.

Genentech Receives Complete Response Letter From FDA For Avastin(R) In Metastatic Breast Cancer (Medical News Today)
Genentech, Inc. today announced that it received a Complete Response Letterfrom the U.S. Food and Drug Administration (FDA) for a supplementalBiologics License Application (sBLA) for Avastin(R) with chemotherapy infirst-line metastatic breast cancer. [click link for full article]

KV Pharmaceutical Company Receives ANDA Approval From U.S. FDA for Six Strengths of Diltiazem HCl ER Capsules (PR Newswire via Yahoo! Finance)
KV Pharmaceutical Company announced today that it has received approval from the U.S. Food and Drug Administration to market six strengths of Diltiazem HCl ER Capsules through its wholly-owned generic/non-branded subsidiary, ETHEX Corporation.